Pontifax Management 4 G.P. (2015) Ltd. 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2020-04-23 4:00 pm Purchase | 2020-04-13 | 13D | Keros Therapeutics, Inc. KROS | Pontifax Management 4 G.P. (2015) Ltd. | 4,734,507 23.600% | 4,734,507 (New Position) | Filing |